Showing results (91-100 of 210) with videos related to

Sort By:
Pageof 21
Annals of Hematology|June 16, 2026
Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysisMarie Harzer, Nils Gross-Fengels, Fede Melzer, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Haematologica|August 28, 2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myelomaHanny Musa, Michał Mielnik, Suzanne Trudel, et al.
Blood Cancer Journal|March 1, 2020
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myelomaTatjana Bilich, Annika Nelde, Jens Bauer, et al.
Blood|July 4, 2015
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapySimon Walz, Juliane S Stickel, Daniel Johannes Kowalewski, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Cancer Immunology, Immunotherapy : CII|April 24, 2025
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cellsElias Brauneck, Leon-Gordian Leonhardt, Anne Marie Assemissen, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
Pageof 21